# Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

> **NCT00396864** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 51 (actual)

## Conditions studied

- Cancer
- Lymphomas

## Interventions

- **DRUG:** NPI-0052

## Key facts

- **NCT ID:** NCT00396864
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396864, "Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00396864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*